loveguli/E+ via Getty Images Avid Bioservices ( NASDAQ: CDMO ) rose 1.6% as a holder said that it's opposed the planned $12.50 a share sale to GHO Capital Partners and Ampersand Capital Partners.
Punch & Associates, which has a 4.5% stake in Avid Biosciences ( CDMO ), said the acquisition "materially undervalues" the.